• In late June 2026, Corcept Therapeutics was removed from both the Russell 1000 Defensive Index and the Russell 1000 Growth-Defensive Index, ending its inclusion in these benchmark portfolios.
• This index removal can influence how quantitatively driven and index-tracking investors view Corcept, potentially shifting demand for the stock as portfolios are rebalanced.
• Next, we’ll examine how Corcept’s removal from key Russell defensive indexes interacts with its existing investment narrative and risks.

The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Corcept Therapeutics Investment Narrative Recap

To own Corcept, you need to believe cortisol modulation can grow beyond Korlym into durable franchises like relacorilant and Lifyorli, while the company manages patent, pricing, and regulatory risks. The key near term catalyst is the FDA’s six month review of relacorilant in Cushing’s, and the biggest current risk is Korlym erosion and litigation outcomes. Corcept’s removal from Russell defensive indexes mainly affects index flows and does not materially change these core drivers.

The most relevant recent update is Corcept’s June 17 resubmission of its NDA for relacorilant in Cushing’s syndrome, triggering a new six month FDA review. This filing is central to reducing single product exposure and could eventually rebalance revenue away from Korlym, especially as an approved oral option alongside Lifyorli in oncology. Against that backdrop, the index removals highlight how sentiment and ownership patterns can shift just as Corcept is pursuing an important diversification milestone.

Yet while Corcept looks more diversified on paper, investors should be aware that...

Corcept Therapeutics' narrative projects $1.9 billion revenue and $910.1 million earnings by 2029. This requires 34.6% yearly revenue growth and about an $863 million earnings increase from $46.7 million today.

Uncover how Corcept Therapeutics' forecasts yield a $88.00 fair value, in line with its current price.

Exploring Other Perspectives

While consensus sees robust growth, the most cautious analysts, who once modeled revenue reaching about US$1.8 billion and earnings of roughly US$558.7 million by 2028, worry index removal plus heavy late stage spending could strain margins and make those outcomes harder to achieve, so it is worth comparing these more pessimistic assumptions with your own view of Corcept’s risks and opportunities.

Explore 5 other fair value estimates on Corcept Therapeutics - why the stock might be worth just $88.00!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Corcept Therapeutics research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free Corcept Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Corcept Therapeutics' overall financial health at a glance.

No Opportunity In Corcept Therapeutics?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 44 companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.